---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-019617"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:45:29.268537+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TARA-002 shows 68% CR at 6 months in BCG-unresponsive NMIBC; no Grade 3+ TRAEs

## Summary
- BCG-Unresponsive cohort: CR rate 68.2% at 6 months (15/22), 33.3% at 12 months (5/15); 61.5% re-induction conversion.
- BCG-Naïve cohort: CR rate 66.7% at 6 months (18/27), 57.9% at 12 months (11/19); 66.7% re-induction conversion.
- No Grade 3 or greater treatment-related adverse events; no discontinuations due to TRAEs; common TRAEs were dysuria (14%), bladder spasm (9%).
- Enrollment completion of BCG-Unresponsive registrational cohort expected 2H 2026; ADVANCED-3 registrational trial for BCG-Naïve to start 2H 2026.
- Data presented at ASCO GU 2026; company hosted conference call on Feb 24, 2026.

## SEC filing metadata
- accession: 0001213900-26-019617
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/0001213900-26-019617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/ea0277972-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-019617
- JSON: https://secwatch.observer/filing/0001213900-26-019617.json
- Plain text: https://secwatch.observer/filing/0001213900-26-019617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.